{"denoms":[{"counts":[{"groupId":"BG000","value":"179"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"358"}],"units":"Participants"}],"groups":[{"description":"Azacitidine, 75 mg/m\\^2/day given by subcutaneous injection for 7 days of every 28 day cycle, plus best supportive care.","id":"BG000","title":"Azacitidine"},{"description":"Physician choice of low dose cytarabine, standard chemotherapy, or best supportive care (consisting of blood products, growth factors, antibiotics)","id":"BG001","title":"Conventional Care"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"7.57","value":"68.0"},{"groupId":"BG001","spread":"7.87","value":"69.2"},{"groupId":"BG002","spread":"7.73","value":"68.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"107"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"119"},{"groupId":"BG002","value":"251"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"177"},{"groupId":"BG001","value":"175"},{"groupId":"BG002","value":"352"}]}],"title":"Caucasian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}],"title":"Asian/Oriental"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}]}],"title":"Hispanic"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}]}],"title":"Other"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"104"},{"groupId":"BG001","value":"103"},{"groupId":"BG002","value":"207"}]}],"title":"Refractory anemia with excess blasts (RAEB)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"123"}]}],"title":"RAEB in transformation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}],"title":"Modified chronic myelomonocytic leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Acute myeloid leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"6"}]}],"title":"Myeloproliferative disease"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"}]}],"title":"Indeterminate"}],"description":"FAB classifications were determined by the Independent Review Committee","paramType":"NUMBER","title":"French-American-British (FAB) Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"18"}]}],"title":"Intermediate risk level 1 (0.5-1.0)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"146"}]}],"title":"Intermediate risk level 2 (1.5-2.0)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"167"}]}],"title":"High risk (2.5-3.5)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}]}],"title":"Not applicable"},{"categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"19"}]}],"title":"Indeterminate"}],"description":"The international prognostic scoring system (IPSS) is a standard for risk assessment in primary myelodysplastic syndromes (MDS) that categorizes prognoses taking into account cytogenetics, cytopenias, blasts and blood counts. The scale is 0-3.5 at .5 increments. Scores of 2.5-3.5 represent high risk which corresponds to poorer prognosis. The assessment was performed by the Independent Review Committee.","paramType":"NUMBER","title":"International Prognostic Scoring System (IPSS)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"31"}]}],"title":"Refractory anemia with excess blasts - 1"},{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"95"},{"groupId":"BG002","value":"193"}]}],"title":"Refractory anemia with excess blasts - 2"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}]}],"title":"Chronic myelomonocytic leukemia - 1 (CMMoL-1)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"15"}]}],"title":"Chronic myelomonocytic leukemia - 2 (CMMoL-2)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"113"}]}],"title":"Acute myeloid leukemia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"}]}],"title":"Indeterminate"}],"description":"WHO classifications were determined by the Independent Review Committee","paramType":"NUMBER","title":"World Health Organization (WHO) Classification","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.19","value":"1.9"},{"groupId":"BG001","spread":"0.19","value":"1.8"},{"groupId":"BG002","spread":"0.19","value":"1.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Surface Area","unitOfMeasure":"meters squared"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.08","value":"76.5"},{"groupId":"BG001","spread":"13.58","value":"74.6"},{"groupId":"BG002","spread":"13.85","value":"75.6"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Weight","unitOfMeasure":"kilograms"}]}